Importance: Seizure risk stratification is needed to boost inpatient seizure detection and to improve continuous electroencephalogram (cEEG) cost-effectiveness. 2HELPS2B can address this need but requires validation. Objective: To use an independent cohort to validate the 2HELPS2B score and develop a practical guide for its use. Design, Setting, and Participants: This multicenter retrospective medical record review analyzed clinical and EEG data from patients 18 years or older with a clinical indication for cEEG and an EEG duration of 12 hours or longer who were receiving consecutive cEEG at 6 centers from January 2012 to January 2019. 2HELPS2B was evaluated with the validation cohort using the mean calibration error (CAL), a measure of the difference between prediction and actual results. A Kaplan-Meier survival analysis was used to determine the duration of EEG monitoring to achieve a seizure risk of less than 5% based on the 2HELPS2B score calculated on first- hour (screening) EEG. Participants undergoing elective epilepsy monitoring and those who had experienced cardiac arrest were excluded. No participants who met the inclusion criteria were excluded. Main Outcomes and Measures: The main outcome was a CAL error of less than 5% in the validation cohort. Results: The study included 2111 participants (median age, 51 years; 1113 men [52.7%]; median EEG duration, 48 hours) and the primary outcome was met with a validation cohort CAL error of 4.0% compared with a CAL of 2.7% in the foundational cohort (P = .13). For the 2HELPS2B score calculated on only the first hour of EEG in those without seizures during that hour, the CAL error remained at less than 5.0% at 4.2% and allowed for stratifying patients into low- (2HELPS2B = 0; <5% risk of seizures), medium- (2HELPS2B = 1; 12% risk of seizures), and high-risk (2HELPS2B, ≥2; risk of seizures, >25%) groups. Each of the categories had an associated minimum recommended duration of EEG monitoring to achieve at least a less than 5% risk of seizures, a 2HELPS2B score of 0 at 1-hour screening EEG, a 2HELPS2B score of 1 at 12 hours, and a 2HELPS2B score of 2 or greater at 24 hours. Conclusions and Relevance: In this study, 2HELPS2B was validated as a clinical tool to aid in seizure detection, clinical communication, and cEEG use in hospitalized patients. In patients without prior clinical seizures, a screening 1-hour EEG that showed no epileptiform findings was an adequate screen. In patients with any highly epileptiform EEG patterns during the first hour of EEG (ie, a 2HELPS2B score of ≥2), at least 24 hours of recording is recommended.
Importance: Seizure risk stratification is needed to boost inpatient seizure detection and to improve continuous electroencephalogram (cEEG) cost-effectiveness. 2HELPS2B can address this need but requires validation. Objective: To use an independent cohort to validate the 2HELPS2B score and develop a practical guide for its use. Design, Setting, and Participants: This multicenter retrospective medical record review analyzed clinical and EEG data from patients 18 years or older with a clinical indication for cEEG and an EEG duration of 12 hours or longer who were receiving consecutive cEEG at 6 centers from January 2012 to January 2019. 2HELPS2B was evaluated with the validation cohort using the mean calibration error (CAL), a measure of the difference between prediction and actual results. A Kaplan-Meier survival analysis was used to determine the duration of EEG monitoring to achieve a seizure risk of less than 5% based on the 2HELPS2B score calculated on first- hour (screening) EEG. Participants undergoing elective epilepsy monitoring and those who had experienced cardiac arrest were excluded. No participants who met the inclusion criteria were excluded. Main Outcomes and Measures: The main outcome was a CAL error of less than 5% in the validation cohort. Results: The study included 2111 participants (median age, 51 years; 1113 men [52.7%]; median EEG duration, 48 hours) and the primary outcome was met with a validation cohort CAL error of 4.0% compared with a CAL of 2.7% in the foundational cohort (P = .13). For the 2HELPS2B score calculated on only the first hour of EEG in those without seizures during that hour, the CAL error remained at less than 5.0% at 4.2% and allowed for stratifying patients into low- (2HELPS2B = 0; <5% risk of seizures), medium- (2HELPS2B = 1; 12% risk of seizures), and high-risk (2HELPS2B, ≥2; risk of seizures, >25%) groups. Each of the categories had an associated minimum recommended duration of EEG monitoring to achieve at least a less than 5% risk of seizures, a 2HELPS2B score of 0 at 1-hour screening EEG, a 2HELPS2B score of 1 at 12 hours, and a 2HELPS2B score of 2 or greater at 24 hours. Conclusions and Relevance: In this study, 2HELPS2B was validated as a clinical tool to aid in seizure detection, clinical communication, and cEEG use in hospitalized patients. In patients without prior clinical seizures, a screening 1-hour EEG that showed no epileptiform findings was an adequate screen. In patients with any highly epileptiform EEG patterns during the first hour of EEG (ie, a 2HELPS2B score of ≥2), at least 24 hours of recording is recommended.
Authors: Aaron F Struck; Gamaleldin Osman; Nishi Rampal; Siddhartha Biswal; Benjamin Legros; Lawrence J Hirsch; M Brandon Westover; Nicolas Gaspard Journal: Ann Neurol Date: 2017-07-19 Impact factor: 10.422
Authors: Gian Marco De Marchis; Deborah Pugin; Emma Meyers; Angela Velasquez; Sureerat Suwatcharangkoon; Soojin Park; M Cristina Falo; Sachin Agarwal; Stephan Mayer; J Michael Schmidt; E Sander Connolly; Jan Claassen Journal: Neurology Date: 2015-12-23 Impact factor: 9.910
Authors: Aaron F Struck; Berk Ustun; Andres Rodriguez Ruiz; Jong Woo Lee; Suzette M LaRoche; Lawrence J Hirsch; Emily J Gilmore; Jan Vlachy; Hiba Arif Haider; Cynthia Rudin; M Brandon Westover Journal: JAMA Neurol Date: 2017-12-01 Impact factor: 18.302
Authors: Nicolas Gaspard; Lawrence J Hirsch; Suzette M LaRoche; Cecil D Hahn; M Brandon Westover Journal: Epilepsia Date: 2014-06-02 Impact factor: 5.864
Authors: Brandon Foreman; Hyunjo Lee; David O Okonkwo; Anthony J Strong; Clemens Pahl; Lori A Shutter; Jens P Dreier; Laura B Ngwenya; Jed A Hartings Journal: Neurocrit Care Date: 2022-02-16 Impact factor: 3.532
Authors: Eric W Moffet; Thanujaa Subramaniam; Lawrence J Hirsch; Emily J Gilmore; Jong Woo Lee; Andres A Rodriguez-Ruiz; Hiba A Haider; Monica B Dhakar; Neville Jadeja; Gamaledin Osman; Nicolas Gaspard; Aaron F Struck Journal: Neurocrit Care Date: 2020-12 Impact factor: 3.210
Authors: Shobhit Singla; Gabriella E Garcia; Grace E Rovenolt; Alexandria L Soto; Emily J Gilmore; Lawrence J Hirsch; Hal Blumenfeld; Kevin N Sheth; S Bulent Omay; Aaron F Struck; M Brandon Westover; Jennifer A Kim Journal: Curr Neurol Neurosci Rep Date: 2020-07-27 Impact factor: 6.030
Authors: Michael B Westover; Lidia M V R Moura; Felipe J S Jones; Paula R Sanches; Jason R Smith; Sahar F Zafar; Sonia Hernandez-Diaz; Deborah Blacker; John Hsu; Lee H Schwamm Journal: Stroke Date: 2021-06-15 Impact factor: 10.170